BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CHEMICON International, Inc. (SERO) And MorphoSys AG Enter Into Worldwide Licensing Agreement For Research Antibodies


1/10/2006 10:47:07 AM

ATLANTA--(BUSINESS WIRE)--Jan. 10, 2006--Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) have signed a three-year agreement for the distribution of HuCAL(R)-based recombinant research antibodies through Chemicon's worldwide sales network. MorphoSys's Antibodies by Design unit will develop antibodies from its proprietary HuCAL GOLD(R) antibody library against targets identified and supplied by Chemicon, a leading provider of research tools. Chemicon may market the licensed HuCAL(R)-based research antibodies for use in in vitro research as stand-alone products or as components of reagent kits. In addition, Chemicon may also market the antibodies for clinical diagnostic applications. The parties are aiming to complete 100 research antibody projects per year over the three year life time of the agreement. MorphoSys receives payment for antibody generation, optional additional fees, and royalties on all products. Further financial details were not disclosed.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES